Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Agilent in Resequencing Co-marketing Pact

NEW YORK (GenomeWeb News) – Illumina and Agilent have entered into a non-exclusive co-marketing agreement focused on researchers conducting targeted resequencing.

The firms jointly announced today that they will co-market Agilent's SureSelect Target Enrichment System with Illumina's Genome Analyzer. They said the combination will provide researchers with a method for efficiently resequencing specific regions of interest in the genome and will enable researchers to conduct studies that otherwise would not be feasible.

"When combined with Illumina's Genome Analyzer, researchers can design their own experiments and take advantage of Illumina's long reads to achieve timely, reproducible results while reducing cost and increasing robustness," Nick Roelofs, GM of Agilent's Life Science Solutions Unit, said in a statement. "The SureSelect System enables scientists to easily and efficiently design custom content through eArray probe design and incorporate automation for scalability and cost efficiencies."

The firms are demonstrating the benefits of the combined technologies this week at the American Association of Cancer Research meeting in Denver. They said that the new research protocol using the combined technologies "enables scientists to interrogate multiple regions of interest in order to detect rare mutations, such as those commonly found in cancer, while taking advantage of low sample input requirements."

Financial and other terms of the collaboration were not disclosed.